What is Dermatomyositis?
Dermatomyositis is a rare, systemic autoimmune disease characterized by distinctive skin manifestations and muscle inflammation, resulting in proximal muscle weakness that develops over weeks to months, with potential involvement of multiple organ systems including the lungs, heart, and gastrointestinal tract. 1
Core Clinical Features
Cutaneous Manifestations
Dermatomyositis presents with pathognomonic skin findings that often precede or accompany muscle disease 1:
- Heliotrope rash: Periorbital edema with violaceous discoloration
- Gottron's papules: Erythematous papules over the extensor surfaces of joints (particularly knuckles, elbows, knees)
- Photosensitive erythematous rash with poikiloderma affecting the face, neck, torso, and extensor surfaces of extremities
- Periungual telangiectasias and cuticular changes
- "V-sign" and "shawl sign" distribution patterns
Less commonly, patients develop cutaneous vasculitis, ulcerations, and calcinosis (more frequent in juvenile dermatomyositis) 1.
Muscle Involvement
The muscle disease manifests as 1:
- Symmetric proximal muscle weakness affecting shoulders and hips
- Elevated muscle enzymes: Creatine kinase (CK), transaminases (AST, ALT), LDH, and aldolase
- Electromyographic abnormalities: Polyphasic motor unit action potentials of short duration and low amplitude, with increased insertional and spontaneous activity including fibrillation potentials and sharp waves
Systemic Complications
Pulmonary involvement ranges from aspiration pneumonia due to ventilatory muscle weakness to interstitial lung disease (ILD), with nonspecific interstitial pneumonitis being the most common pattern 1. This can significantly impact mortality and morbidity.
Cardiac manifestations may include asymptomatic arrhythmias (such as sinus tachycardia) and diastolic dysfunction 1.
Gastrointestinal involvement includes dysphagia related to cricopharyngeal weakness or spasm, detectable on videofluoroscopy 1.
Disease Subtypes and Autoantibodies
Myositis-specific autoantibodies define distinct clinical phenotypes and predict outcomes 1, 2:
- Anti-Mi2: Classic dermatomyositis presentation
- Anti-MDA5: Associated with rapidly progressive ILD, particularly high-risk
- Anti-NXP2: Linked to calcinosis and malignancy risk
- Anti-TIF1γ: Strong association with cancer-associated dermatomyositis
- Anti-SAE: Distinct cutaneous and systemic features
Juvenile Dermatomyositis
Juvenile dermatomyositis affects children younger than 18 years and has distinct features 1:
- Proximal muscle weakness
- Calcinosis cutis (more common than in adults)
- Cutaneous vasculitis and ulcerations
- Vasculopathy affecting the gastrointestinal tract
Malignancy Association
Cancer-associated dermatomyositis occurs in approximately 20% of adult patients 3, with the highest risk in the three years before or after dermatomyositis diagnosis 4. The most common associated malignancies are breast and lung cancers 4. Risk is particularly elevated in patients over age 40 at diagnosis 4.
Diagnostic Approach
Diagnosis requires correlation of 1, 5:
- Clinical examination: Characteristic skin findings and muscle weakness pattern
- Laboratory testing: Elevated muscle enzymes, myositis-specific autoantibodies
- Imaging: MRI with T2-weighted fat-suppressed sequences to identify muscle inflammation 1
- Electromyography: When diagnosis is uncertain
- Muscle biopsy: Reserved for cases with diagnostic uncertainty
The 2017 EULAR/ACR classification criteria use a weighted scoring system, with a probability cutoff of 55% (score of 5.5 without biopsy, 6.7 with biopsy) recommended for classification 5.
Prognosis and Outcomes
With early treatment, 30-50% of patients can achieve remission within 2-3 years with few complications and mortality under 4% 6. However, polycyclic or persistently active disease occurs in 41-60% of cases 6. Complications including calcinosis, persistent muscle weakness, and skin or muscle atrophy remain problematic and negatively impact quality of life 6, 7.
The key to improving outcomes is early recognition and prompt initiation of immunosuppressive therapy, as delayed treatment increases risk of lipodystrophy, calcinosis, and irreversible organ damage 6.